^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    1d
    The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study (clinicaltrials.gov)
    P=N/A, N=300, Completed, Sun Yat-sen University
    New trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    1d
    Study of PAT in Patients With Solid Tumor Cancers (clinicaltrials.gov)
    P1, N=21, Recruiting, Masonic Cancer Center, University of Minnesota | Suspended --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab)
    1d
    Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Sep 2025 --> Apr 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Tecentriq (atezolizumab)
    1d
    IMMUNO-TH: Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Dec 2028 --> Jan 2030 | Trial primary completion date: May 2028 --> Jan 2030
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    2d
    The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes. (PubMed, JHEP Rep)
    These findings provide both a valuable guide for determining treatment strategies in routine clinical practice and a foundation for future immunotherapy development for the treatment of advanced hepatocellular carcinoma. The study protocol was registered on the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) (UMIN000047701).
    Journal • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    2d
    A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=160, Not yet recruiting, Yonsei University
    New P1/2 trial • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab) • venadaparib (NOV 1401)
    2d
    IMpALA: A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, The Christie NHS Foundation Trust | N=42 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Bavencio (avelumab) • aspirin
    2d
    Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib) • etoposide oral • Enweida (envafolimab)
    2d
    A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation. (PubMed, Cancer Med)
    Our study demonstrated modest clinical benefits of D + O with ORR of 28.6% in subsets of heavily pretreated TNBC. Further detailed classification of DCs to understand the predictive role of DCs and prospective validation in a large cohort is required.
    P2 data • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    2d
    ANTELOPE: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (clinicaltrials.gov)
    P4, N=136, Recruiting, Nikolaj Frost MD | Trial primary completion date: Oct 2025 --> Feb 2026
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • NKX2-1 (NK2 Homeobox 1)
    |
    EGFR mutation • ALK rearrangement
    |
    Keytruda (pembrolizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    2d
    Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=21, Recruiting, Mary Feng, MD | Trial completion date: Feb 2027 --> Jul 2029 | Trial primary completion date: Feb 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    RJBLC-NEBC001: Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma (clinicaltrials.gov)
    P2, N=22, Recruiting, RenJi Hospital | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • etoposide IV • AiRuiLi (adebrelimab)